TY - JOUR
T1 - Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma
T2 - 12-year results
AU - Khouri, Issa F.
AU - Saliba, Rima M.
AU - Erwin, William D.
AU - Samuels, Barry I.
AU - Korbling, Martin
AU - Medeiros, L. Jeffrey
AU - Valverde, Rosamar
AU - Alousi, Amin M.
AU - Anderlini, Paolo
AU - Bashir, Qaiser
AU - Ciurea, Stefan
AU - Gulbis, Alison M.
AU - De Lima, Marcos
AU - Hosing, Chitra
AU - Kebriaei, Partow
AU - Popat, Uday R.
AU - Fowler, Nathan
AU - Neelapu, Sattva S.
AU - Samaniego, Felipe
AU - Champlin, Richard E.
AU - Macapinlac, Homer A.
PY - 2012/6/28
Y1 - 2012/6/28
N2 - In 2008, we reported favorable 5-year outcomes of nonmyeloablative allogeneic stem cell transplantation after fludarabine, cyclophosphamide, rituximab (FCR) conditioning for relapsed and chemosensitive follicular lymphoma. However, innovative strategies were still needed to treat patients with chemorefractory disease. We therefore subsequently performed a trial in which 90Y-ibritumomab tiuxetan (0.4 mCi/kg) was added to the fludarabine, cyclophosphamide conditioning regimen (90YFC). Here, we report updated results of the FCR trial and outcomes after 90YFC. For the FCR group (N = 47), since the last update, one patient developed recurrent disease. With a median follow-up of 107 months (range, 72-142 months), the 11-year overall survival and progression-free survival rates were 78%, and 72%, respectively. For the 90YFC group (N = 26), more patients had chemorefractory disease than did those in the FCR group (38% and 0%, P < .001). With a median follow-up of 33 months (range,17-94 months), the 3-year progression-free survival rates for patients with chemorefractory and chemosensitive disease were 80% and 87%, respectively (P = .7). The low frequency of relapse observed after a long follow-up interval of 9 years in the FCR group suggests that these patients are cured of their disease. The addition of 90Y to the conditioning regimen appears to be effective in patients with chemorefractory disease. This trial was registered at www.clinicaltrials.gov as NCT00048737.
AB - In 2008, we reported favorable 5-year outcomes of nonmyeloablative allogeneic stem cell transplantation after fludarabine, cyclophosphamide, rituximab (FCR) conditioning for relapsed and chemosensitive follicular lymphoma. However, innovative strategies were still needed to treat patients with chemorefractory disease. We therefore subsequently performed a trial in which 90Y-ibritumomab tiuxetan (0.4 mCi/kg) was added to the fludarabine, cyclophosphamide conditioning regimen (90YFC). Here, we report updated results of the FCR trial and outcomes after 90YFC. For the FCR group (N = 47), since the last update, one patient developed recurrent disease. With a median follow-up of 107 months (range, 72-142 months), the 11-year overall survival and progression-free survival rates were 78%, and 72%, respectively. For the 90YFC group (N = 26), more patients had chemorefractory disease than did those in the FCR group (38% and 0%, P < .001). With a median follow-up of 33 months (range,17-94 months), the 3-year progression-free survival rates for patients with chemorefractory and chemosensitive disease were 80% and 87%, respectively (P = .7). The low frequency of relapse observed after a long follow-up interval of 9 years in the FCR group suggests that these patients are cured of their disease. The addition of 90Y to the conditioning regimen appears to be effective in patients with chemorefractory disease. This trial was registered at www.clinicaltrials.gov as NCT00048737.
UR - http://www.scopus.com/inward/record.url?scp=84863506635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863506635&partnerID=8YFLogxK
U2 - 10.1182/blood-2012-03-417808
DO - 10.1182/blood-2012-03-417808
M3 - Article
C2 - 22586182
AN - SCOPUS:84863506635
SN - 0006-4971
VL - 119
SP - 6373
EP - 6378
JO - Blood
JF - Blood
IS - 26
ER -